MEMBRANE AUTOTRANSFUSION SYSTEM

膜自体输血系统

• 批准号: 3501869
• 负责人: UDIPI R SHETTIGAR
• 金额: $ 5万
• 依托单位: BIOPROCESS SYSTEMS
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-08-01 至 1992-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3501869
• 关键词: autotransfusion; bioengineering /biomedical engineering; biomedical equipment development; blood cell count; blood filtration; blood treatment; cow; hemodialysis; hemoglobin; hollow fiber separation technique; human tissue; membrane model

Intraoperative autotransfusion system (IOAT) aspirates waste blood from surgical wound site, purifies and returns it to the same patient. We developed and evaluated in-vivo a new IOAT system which is designed to purify the aspirated waste blood using hollow fiber membrane ultrafilter/plasma filters instead of using centrifuges, and return the purified whole blood to the patient in a closed loop continuous on line operation within a few minutes without significant wastage of blood cells and clotting factors. Preliminary in-vivo evaluations of our Membrane Autotransfusion System (MATS) during implantation of artificial ventricles in calves have lead us to redefine the design parameters. We rebuilt our MATS so that it could respond to the rapidly changing operating conditions, such as blood flow rate (o to 2,000 ml/min, hematocrit (o to 45%), air emboli & froth, macroaggregates, irrigating fluid, shear rate, transmembrane pressure, duration of operation, and systemic heparinization. Phase-I involves extensive in-vivo studies using calf and human blood with an objective to establish the consistency of performance of the system in response to the rapid changes in operating conditions. Phase- II involves evaluations (i) during total artificial heart implantation studies in calves, and (ii) in ten calves, where bleeding will be simulated in open chest cavity, and the shed blood will be salvaged by our membrane autotransfusion system. Total available market is expected to be over $120,000,000 in the U.S. There is a strong need for this device in view of the present scare in donor blood transfusions related to transmission of AIDS and hepatitis.

术中自体输血系统(IOAT)抽吸术中 手术伤口处，净化并归还给同一个病人。我们 开发并在体内评估一种新的IOAT系统，该系统旨在 中空纤维膜净化抽吸废血的研究 超滤器/血浆过滤器而不是使用离心机，并将 全血纯化后的闭环连续在线给患者 在几分钟内完成手术，不会造成大量的血液流失 细胞和凝血因子。 膜自体输血系统的初步体内评价 小牛植入人工脑室时(垫)含铅 美国重新定义设计参数。我们重建了我们的垫子，以便它 可以对快速变化的运行条件做出反应，例如 血流率(0-2,000毫升/分钟，红细胞压积(0-45%)，空气栓子 泡沫、大团聚体、灌溉液、剪切率、跨膜 压力、手术持续时间和全身肝素化。 第一阶段包括使用小牛和人血进行广泛的体内研究。 目标是建立业绩的一致性 系统响应运行条件的快速变化。阶段- II涉及评估(I)在全人工心脏植入期间 对小牛进行研究，以及(Ii)在10头小牛中进行研究，其中出血将 在开放的胸腔内模拟，流出的血液将被 我们的膜自体输血系统。预计可用市场总量 在美国超过12000万美元。这是一个强烈的需求 针对目前装置在献血员输血方面的恐慌 艾滋病和肝炎的传播。